- Chiesi Group has expanded its partnership with Bespak to increase pressurized metered dose inhaler (pMDI) manufacturing capacity at Bespak’s Holmes Chapel facility in the UK.
- The collaboration supports the next phase of Chiesi’s Carbon Minimal Inhaler (CMI) program, designed to reduce the carbon footprint of pMDIs by up to 90%.
Chiesi Group has expanded its collaboration with Bespak to increase manufacturing capacity for pressurized metered dose inhalers (pMDIs) at Bespak’s Holmes Chapel facility in the United Kingdom. The agreement supports the next phase of Chiesi’s Carbon Minimal Inhaler (CMI) program, which aims to reduce the environmental impact of inhaled therapies.
Bespak operates as a CDMO specializing in inhalation drug delivery and contract manufacturing for pulmonary and nasal therapies. Under the expanded partnership, the Holmes Chapel site will increase production capacity to support the scale-up of inhalers using next-generation propellants with lower global warming potential.
The CMI program focuses on reducing the carbon footprint of pMDIs by transitioning to a low global warming potential propellant while maintaining existing treatment options for patients. According to the companies, the change could reduce the carbon footprint of pMDIs by up to 90%.
“At Chiesi, sustainability is not an add-on; it is a commitment that guides our strategic choices.”
Maria Paola Chiesi, Vice Chair of Chiesi Group
The Holmes Chapel facility, located in the North West of England, serves as a manufacturing hub for inhalation products and contributes to the region’s cluster of inhalation research and manufacturing capabilities. The expanded collaboration aims to support the transition to lower-carbon inhalers while maintaining supply of respiratory therapies for patients.
